title: A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.
abstract: OBJECTIVE
  To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients.
  
  
  METHODS
  Parallel-group, randomized, open-label, multicentre study.
  
  
  METHODS
  One hundred and sixty-three patients with HIV predicted to be sensitive to APV, another PI and a nucleoside reverse transcriptase inhibitor (NRTI) were randomly assigned to receive either APV boosted with low-dose RTV (APV/r) or a standard of care (SOC) PI with or without low-dose RTV. The non-inferiority of APV/r to the SOC PIs was assessed by time-weighted average change from baseline (AAUCMB) in plasma viral load (vRNA) at week 16.
  
  
  RESULTS
  The antiviral response for APV/r bid was non-inferior to that for the SOC PI group: the vRNA AAUCMB mean treatment difference was 0.043 log(10) HIV-1 RNA copies/mL [95% confidence interval (CI)-0.250, 0.335]. APV/r bid was generally well tolerated.
  
  
  CONCLUSIONS
  Results confirm the antiviral activity, short-term safety and tolerability of APV/r bid in PI-experienced patients.
authors.affiliation: Hospital Doce de Octubre, Madrid, Spain. fpulido@nacom.es
authors.forename: F
authors.initials: F
authors.lastname: Pulido
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: M
authors.initials: M
authors.lastname: Marquez
authors.forename: R
authors.initials: R
authors.lastname: Thomas
authors.forename: N
authors.initials: N
authors.lastname: Clumeck
authors.forename: R de J
authors.initials: Rde J
authors.lastname: Pedro
authors.forename: A M
authors.initials: AM
authors.lastname: Cattelan
authors.forename: C
authors.initials: C
authors.lastname: Zhu
authors.forename: P
authors.initials: P
authors.lastname: Tymkewycz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002219:Carbamates; D005260:Female; D005663:Furans; D005814:Genes, Viral; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir